Advertisement

Zolpidem Use Among Inpatients Associated with Higher Rate of Falls — Physician’s First Watch

Medical News |
November 20, 2012

Zolpidem Use Among Inpatients Associated with Higher Rate of Falls

Inpatients who were given zolpidem were six times more likely to fall than patients who were prescribed the drug but didn't take it, according to a cohort study in the Journal of Hospital Medicine.

Researchers assessed zolpidem prescriptions among all non-ICU, non-pregnant inpatients at the Mayo Clinic in 2010. After adjusting for factors such as delirium and insomnia, patients who were administered zolpidem had a higher rate of falls than those who did not take zolpidem (3.04 vs. 0.71 falls per 100 patients). The authors estimate for every 55 patients treated with zolpidem, one additional fall could be expected to occur.

They note that at their institution, order sets have been changed to discourage use of zolpidem, and they recommend that other hospitals follow suit.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement